Studies examining zinc transporters in cardiovascular disease
| Zinc transporter . | Experimental model . | Protocol . | Quantification . | Expression change . | Reference . | |
|---|---|---|---|---|---|---|
| Protein expression . | mRNA expression . | |||||
| ZIP1 | CMs isolated from Sprague-Dawley rats (WT, male, 8 wk) | In vivo chronic aldosterone/salt treatment, 4 wk | ✓ | ↑ ∼4.2-fold | Kamalov et al., 2009 | |
| CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼1.4 AU ↑ H/R 0.5 to ∼0.7 AU | Bodiga et al., 2017 | ||
| ZIP2 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼1.3 AU ↓ H/R 1 to ∼0.8 AU (NS) | Bodiga et al., 2017 | |
| Hearts from C57BL/6 mice (WT, male, 8–10 wk) | In vivo I/R by left anterior descending coronary artery occlusion | ✓ | ✓ | ↑ protein ∼150% ↑ mRNA ∼fourfold | Du et al., 2019 | |
| ZIP3 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼1.6 AU ↑ H/R 1 to ∼1.6 AU | Bodiga et al., 2017 | |
| ZIP6 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.8 to ∼1 AU (NS) ↓ H/R 0.8 to ∼0.7 AU (NS) | Bodiga et al., 2017 | |
| ZIP7 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ↓ H/R 1 to ∼0.9 AU (NS) | Bodiga et al., 2017 | |
| ZIP7 | Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↑ ∼twofold | Olgar et al., 2018b | |
| H9C2 cell lysates | In vitro DOX treatment | ✓ | ↑ ∼1.5-fold | Tuncay et al., 2019 | ||
| CMs isolated from C57BL/6 mice (WT, male, 8–10 wk) | In vitro H/R | ✓ | ↑ ∼0.7 to ∼1.2 | Zhang et al., 2021 | ||
| Hearts from Wistar rats (WT, male, 250–350 g) | Ex vivo I/R | ✓ | ↑ ∼0.75 to ∼0.9 | Zhang et al., 2021 | ||
| Hearts from C57BL/6 mice (WT, male, 8–10 wk) | In vivo I/R by left anterior descending coronary artery occlusion | ✓ | ✓ | ↑ protein ∼0.8 to ∼1 ↑ mRNA from ∼1 to 2 | Zhang et al., 2021 | |
| ZIP8 | H9C2 cell lysates | In vitro DOX treatment | ✓ | ↓ ∼0.4-fold | Olgar et al., 2018a | |
| Human heart failure tissue | Patients with end-stage heart failure | ✓ | ↓ ∼0.5-fold | Olgar et al., 2018a | ||
| Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↓ ∼0.5-fold | Olgar et al., 2018b | ||
| ZIP9 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| ZIP10 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼1.5 AU ↑ H/R 1–∼1.2 (NS) | Bodiga et al., 2017 | |
| ZIP11 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| ZIP12 | Human pulmonary artery smooth muscle cells | In vitro hypoxia incubation | ✓ | ↑ ∼threefold | Zhao et al., 2015 | |
| ZIP13 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| ZIP13 | Heart tissue from C57BL/6 mice (WT, male, 8–10 wk) | In vivo left anterior descending coronary artery ligation | ✓ | ✓ | ↓ protein ∼0.5-fold ↓ mRNA ∼0.6-fold | Wang et al., 2021a |
| H9C2 cell lysates | In vitro H/R | ✓ | ↓ ∼0.6-fold | Wang et al., 2021b | ||
| Neonatal CMs isolated from newborn C57BL/6N mice | In vitro DOX treatment | ✓ | ↓ ∼0.75 to ∼0.1 | Hara et al., 2022 | ||
| Heart tissue from C57BL/6N mice | In vivo intraperitoneal DOX injection | ✓ | ↓ ∼1 to ∼0.6 | Hara et al., 2022 | ||
| ZIP14 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| H9C2 cell lysates | In vitro DOX treatment | ✓ | ↑ ∼1.5-fold | Olgar et al., 2018a | ||
| Human heart failure tissue | Patients with end-stage heart failure | ✓ | ↑ ∼twofold | Olgar et al., 2018a | ||
| Heart tissue from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↑ ∼2.5-fold | Olgar et al., 2018b | ||
| ZnT1 | Cultures CMs from rats (1–2 d old) | In vitro rapid pacing | ✓ | ↑ 214.4% | Beharier et al., 2007 | |
| Heart homogenates from Sprague-Dawley rats (WT, male, 250–350 g) | In vivo rapid atrial pacing | ✓ | ↑ 148% | Beharier et al., 2007 | ||
| Human cardiac tissue | Cardiac tissue obtained from control and atrial fibrillation patients | ✓ | ↑ 0.73–1.88 | Etzion et al., 2008 | ||
| CMs from Sprague-Dawley rats (WT, male, 8 wk) | In vivo chronic aldosterone/salt treatment, 4 wk | ✓ | ↑ ∼twofold | Kamalov et al., 2009 | ||
| CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ↑ 1 to ∼1.2 AU (NS) | Bodiga et al., 2017 | ||
| ZnT2 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼0.6 AU (NS) ↑ H/R 0.4 to ∼1.4 AU | Bodiga et al., 2017 | |
| ZnT5 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ≈ hypoxia ↑ H/R 0.8 to 1.2 AU | Bodiga et al., 2017 | |
| ZnT7 | Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↓ ∼0.6-fold | Olgar et al., 2018b | |
| H9C2 cell lysates | In vitro DOX treatment | ✓ | ↓ ∼0.5-fold | Tuncay et al., 2019 | ||
| ZnT8 | H9C2 cell lysates | In vitro DOX treatment | ✓ | ↑ ∼1.6-fold | Olgar et al., 2018a | |
| Human heart failure tissue | Patients with end-stage heart failure | ✓ | ↑ ∼twofold | Olgar et al., 2018a | ||
| Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↑ ∼1.5-fold | Olgar et al., 2018b | ||
| ZnT9 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.8 to ∼1 AU (NS) ↑ H/R 0.8 to ∼1.1 AU (NS) | Bodiga et al., 2017 | |
| Zinc transporter . | Experimental model . | Protocol . | Quantification . | Expression change . | Reference . | |
|---|---|---|---|---|---|---|
| Protein expression . | mRNA expression . | |||||
| ZIP1 | CMs isolated from Sprague-Dawley rats (WT, male, 8 wk) | In vivo chronic aldosterone/salt treatment, 4 wk | ✓ | ↑ ∼4.2-fold | Kamalov et al., 2009 | |
| CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼1.4 AU ↑ H/R 0.5 to ∼0.7 AU | Bodiga et al., 2017 | ||
| ZIP2 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼1.3 AU ↓ H/R 1 to ∼0.8 AU (NS) | Bodiga et al., 2017 | |
| Hearts from C57BL/6 mice (WT, male, 8–10 wk) | In vivo I/R by left anterior descending coronary artery occlusion | ✓ | ✓ | ↑ protein ∼150% ↑ mRNA ∼fourfold | Du et al., 2019 | |
| ZIP3 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼1.6 AU ↑ H/R 1 to ∼1.6 AU | Bodiga et al., 2017 | |
| ZIP6 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.8 to ∼1 AU (NS) ↓ H/R 0.8 to ∼0.7 AU (NS) | Bodiga et al., 2017 | |
| ZIP7 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ↓ H/R 1 to ∼0.9 AU (NS) | Bodiga et al., 2017 | |
| ZIP7 | Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↑ ∼twofold | Olgar et al., 2018b | |
| H9C2 cell lysates | In vitro DOX treatment | ✓ | ↑ ∼1.5-fold | Tuncay et al., 2019 | ||
| CMs isolated from C57BL/6 mice (WT, male, 8–10 wk) | In vitro H/R | ✓ | ↑ ∼0.7 to ∼1.2 | Zhang et al., 2021 | ||
| Hearts from Wistar rats (WT, male, 250–350 g) | Ex vivo I/R | ✓ | ↑ ∼0.75 to ∼0.9 | Zhang et al., 2021 | ||
| Hearts from C57BL/6 mice (WT, male, 8–10 wk) | In vivo I/R by left anterior descending coronary artery occlusion | ✓ | ✓ | ↑ protein ∼0.8 to ∼1 ↑ mRNA from ∼1 to 2 | Zhang et al., 2021 | |
| ZIP8 | H9C2 cell lysates | In vitro DOX treatment | ✓ | ↓ ∼0.4-fold | Olgar et al., 2018a | |
| Human heart failure tissue | Patients with end-stage heart failure | ✓ | ↓ ∼0.5-fold | Olgar et al., 2018a | ||
| Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↓ ∼0.5-fold | Olgar et al., 2018b | ||
| ZIP9 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| ZIP10 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼1.5 AU ↑ H/R 1–∼1.2 (NS) | Bodiga et al., 2017 | |
| ZIP11 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| ZIP12 | Human pulmonary artery smooth muscle cells | In vitro hypoxia incubation | ✓ | ↑ ∼threefold | Zhao et al., 2015 | |
| ZIP13 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| ZIP13 | Heart tissue from C57BL/6 mice (WT, male, 8–10 wk) | In vivo left anterior descending coronary artery ligation | ✓ | ✓ | ↓ protein ∼0.5-fold ↓ mRNA ∼0.6-fold | Wang et al., 2021a |
| H9C2 cell lysates | In vitro H/R | ✓ | ↓ ∼0.6-fold | Wang et al., 2021b | ||
| Neonatal CMs isolated from newborn C57BL/6N mice | In vitro DOX treatment | ✓ | ↓ ∼0.75 to ∼0.1 | Hara et al., 2022 | ||
| Heart tissue from C57BL/6N mice | In vivo intraperitoneal DOX injection | ✓ | ↓ ∼1 to ∼0.6 | Hara et al., 2022 | ||
| ZIP14 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼2 AU ≈ H/R | Bodiga et al., 2017 | |
| H9C2 cell lysates | In vitro DOX treatment | ✓ | ↑ ∼1.5-fold | Olgar et al., 2018a | ||
| Human heart failure tissue | Patients with end-stage heart failure | ✓ | ↑ ∼twofold | Olgar et al., 2018a | ||
| Heart tissue from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↑ ∼2.5-fold | Olgar et al., 2018b | ||
| ZnT1 | Cultures CMs from rats (1–2 d old) | In vitro rapid pacing | ✓ | ↑ 214.4% | Beharier et al., 2007 | |
| Heart homogenates from Sprague-Dawley rats (WT, male, 250–350 g) | In vivo rapid atrial pacing | ✓ | ↑ 148% | Beharier et al., 2007 | ||
| Human cardiac tissue | Cardiac tissue obtained from control and atrial fibrillation patients | ✓ | ↑ 0.73–1.88 | Etzion et al., 2008 | ||
| CMs from Sprague-Dawley rats (WT, male, 8 wk) | In vivo chronic aldosterone/salt treatment, 4 wk | ✓ | ↑ ∼twofold | Kamalov et al., 2009 | ||
| CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 1 to ∼2 AU ↑ 1 to ∼1.2 AU (NS) | Bodiga et al., 2017 | ||
| ZnT2 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.5 to ∼0.6 AU (NS) ↑ H/R 0.4 to ∼1.4 AU | Bodiga et al., 2017 | |
| ZnT5 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ≈ hypoxia ↑ H/R 0.8 to 1.2 AU | Bodiga et al., 2017 | |
| ZnT7 | Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↓ ∼0.6-fold | Olgar et al., 2018b | |
| H9C2 cell lysates | In vitro DOX treatment | ✓ | ↓ ∼0.5-fold | Tuncay et al., 2019 | ||
| ZnT8 | H9C2 cell lysates | In vitro DOX treatment | ✓ | ↑ ∼1.6-fold | Olgar et al., 2018a | |
| Human heart failure tissue | Patients with end-stage heart failure | ✓ | ↑ ∼twofold | Olgar et al., 2018a | ||
| Hearts from Wistar rats (WT, male, 2 mo) | In vivo transverse aortic constriction | ✓ | ↑ ∼1.5-fold | Olgar et al., 2018b | ||
| ZnT9 | CMs isolated from Wistar Kyoto rats | In vitro H/R | ✓ | ↑ hypoxia 0.8 to ∼1 AU (NS) ↑ H/R 0.8 to ∼1.1 AU (NS) | Bodiga et al., 2017 | |
Changes observed in ZIPs and ZnTs in conditions of cardiovascular disease including experimental model, expression change, and study. All expression changes are significant except where NS (not significant) is specified. CMs, cardiomyocytes; DOX, doxorubicin; H/R, hypoxia/reoxygenation. ↑ denotes increased expression; ↓ illustrates a decrease in expression; ≈ shows no change.